NASDAQ: CASI | 中文 | Contact Us

Board of Directors

Wei-Wu He, Ph.D., Chairman & Chief Executive Officer

Dr. He has been Chairman of the Company since February 2012 and Executive Chairman since February 2018 and Chief Executive Officer since 2019. Prior to joining CASI, Dr. He was the CEO of OriGene Technologies, Inc. and remains Chairman of the Board of Directors. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 60 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 32 issued patents. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and received an M.B.A. degree from the Wharton School.

James Huang

Mr. Huang has been a Director of the Company since April 2013. Mr. Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007. Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Meanwhile, James Huang is also founding partner of Panacea Venture, a global venture fund focusing on investments in innovative and transformative early and growth stage healthcare and life science companies. James is Chairman of the Board at Kindstar Global (Beijing) Technology, Inc., Windtree Therapeutics, Inc., JHL Biotech, Inc., Tactiva Therapeutics, LLC, and Chime Biologics Limited and Director at ZIOPHARM Oncology, Inc. and XW Laboratories Inc. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Quan Zhou, Ph.D.

Dr. Zhou has been a director of the Company since June 2016. Dr. Zhou served as the president of IDG Technology Venture Investment Inc. from mid-1990’s until 2012. He has been the managing member of IDG Technology Venture Investments, LP and its successor funds since 2000 and the director of various IDG-Accel China funds since 2005. He currently also serves as the director of IDG China Venture Capital Fund IV L.P. and IDG China Capital Fund III L.P. He serves on the boards of public companies, including Fang Holdings Ltd. (also known as Soufun Holdings Limited) since 1999, Xunlei Limited since 2006, and Yirendai Limited since 2015, and serves on the boards of various private companies, including Superdata Software Holdings Limited, Memsic Inc. and Circle Internet Financial Limited. He has won awards from NASA and holds two U.S. patents in fiber optic devices. Benefiting from more than 20 years of successful financing, business and operation experience, he has established close connections with numerous IT companies and entrepreneurial communities in both China and the United States. He received a Ph.D. in Fiber Optics from Rutgers University in 1989, a Master’s Degree in Chemical Physics from the Chinese Academy of Science in 1985, and a Bachelor’s Degree in Chemical Science from China Science and Technology University in 1982. Dr. Zhou’s qualifications to serve on the Board of Directors, as well as serving as the Chair of the Compensation Committee, include his substantial business experience, particularly in China.

Rajesh C. Shrotriya, MD

Dr. Shrotriya has been a Director of the Company since September 2014. From September 2000 to August 2002, Dr. Shrotriya was President and Chief Operating Officer of NeoTherapeutics, Inc. From 2002 – 2017, Dr. Shrotriya was President and Chief Operating Officer and Chief Executive Officer of Spectrum Pharmaceuticals. In this capacity he spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. Prior to joining Spectrum, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.

Y. Alexander Wu, Ph.D.

Dr. Wu has been a Director of the Company since April 2013. From 2006 to 2017, Dr. Wu was co-founder and Chief Executive Officer of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 600 employees. The company was acquired by JSR for over $400 million in 2017. Before co-founding Crown Bioscience, Dr. Wu was Chief Business Officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was Chief Operating Officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was Manager of Business Development and Strategic Planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.

Franklin C. Salisbury, Jr.

Mr. Salisbury has been a Director of the Company since June 2014. Since 1998, Mr. Salisbury has been President of the National Foundation for Cancer Research (NFCR), an organization that supports healthcare companies and research institutions in order to accelerate new approaches to preventing, diagnosing and treating cancer. Under his leadership, NFCR has forged greater collaboration among scientists at universities, research hospitals and pharmaceutical companies in the U.S. and China in an effort to bring new and innovative care to cancer patients. Mr. Salisbury also led NFCR to launch several research consortia that have enabled cancer researchers to pool their resources and reduce duplicative efforts, thereby accelerating discoveries being made and reducing the cost of achieving them. Mr. Salisbury holds a B.A. in economics from Yale, a Juris Doctor, J.D., from the University of Georgia School of Law, a Masters of Arts degree from the University of Chicago, and an M.Div. from Yale Divinity School.

Committee Membership

Director Audit Compensation
Wei-Wu He, Chairman & CEO
James Huang X (chairman and financial expert)
Quan Zhou X (chairman)
Franklin C. Salisbury, Jr. X X
Rajesh C. Shrotriya
Y. Alexander Wu X X

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More